Drug Trial Radar · NCT07272434
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25,000
Planned (sponsor's estimate)
Start
Oct 22, 2025
Primary completion
Jul 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- MAXVAX Biotechnology Limited Liability CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- Henan Center for Disease Control and Prevention; Hunan Provincial Center for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Shaanxi Provincial Center for Disease Control and Prevention; Guangdong Center for Disease Prevention and Control; Shandong Province Centers for Disease Control and Prevention; Sichuan Center for Disease Control and Prevention; Hebei CDC ,China
- First posted
- Dec 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)Biological
0.5 mL per dose
Placebo (Saline solution)Biological
0.5 mL per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Center for Disease Control and Prevention
Guangzhou, Guangdong, China · Not yet recruiting
Hebei Provincial Center for Disease Control and Prevention
Shijiazhuang, Hebei, China · Active not recruiting
Henan Center for Disease Control and Prevention
Zhengzhou, Henan, China · Recruiting
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China · Recruiting
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China · Recruiting
Shaanxi Provincial Center for Disease Control and Prevention
Xi'an, Shaanxi, China · Recruiting
Shandong Province Centers for Disease Control and Prevention
Jinan, Shandong, China · Active not recruiting
Sichuan Center for Disease Control and Prevention
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.